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Abstract
Serine protease inhibitors (SERPINs) appear to be ubiquitously expressed in a variety of species and play important roles in
pivotal physiological processes such as angiogenesis, immune responses, blood coagulation and fibronolysis. Of these,
squamous cell carcinoma antigen 1 (SCCA1), also known as a SERPINB3, was first identified in squamous cell carcinoma
tissue from the cervix of women. However, there is little known about the SERPINB3 expression in human epithelial ovarian
cancer (EOC). Therefore, in the present study, we investigated the functional role of SERPINB3 gene in human EOC using
chickens, the most relevant animal model. In 136 chickens, EOC was found in 10 (7.4%). SERPINB3 mRNA was induced in
cancerous, but not normal ovaries of chickens (P,0.01), and it was abundant only in the glandular epithelium of cancerous
ovaries of chickens. Further, several microRNAs, specifically miR-101, miR-1668 and miR-1681 were discovered to influence
SERPINB3 expression via its 39-UTR which suggests that post-transcriptional regulation influences SERPINB3 expression in
chickens. SERPINB3 protein was localized predominantly to the glandular epithelium in cancerous ovaries of chickens, and it
was abundant in the nucleus of both chicken and human ovarian cancer cell lines. In 109 human patients with EOC, 15
(13.8%), 66 (60.6%) and 28 (25.7%) patients showed weak, moderate and strong expression of SERPINB3 protein,
respectively. Strong expression of SERPINB3 protein was a prognostic factor for platinum resistance (adjusted OR; odds ratio,
5.94; 95% Confidence Limits, 1.21–29.15), and for poor progression-free survival (PFS; adjusted HR; hazard ratio, 2.07; 95% CI;
confidence interval, 1.03–4.41). Therefore, SERPINB3 may play an important role in ovarian carcinogenesis and be a novel
biomarker for predicting platinum resistance and a poor prognosis for survival in patients with EOC.
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Introduction
Epithelial ovarian cancer (EOC) is the 7th leading cause of
cancer-related deaths in women worldwide [1,2]. The clinical
importance has grown to a greater extent because there are no
relevant symptoms and no effective screening methods for early
detection [3], which leads to International Federation of Gyne-
cologist (FIGO) Stages III-IV disease at the time of diagnosis in
over 75% of patients with EOC [4]. Although early-stage disease,
well differentiation, platinum sensitivity and optimal cytoreductive
surgery have been suggested as favorable prognostic factors, but
their value in prognosis has not been improved markedly [5].
Therefore, the early detection of EOC and prediction of prognosis
for patient survival using specific biomarkers is increasingly
recognized as a better approach to overcome these limitations.
For this purpose, genetically manipulated rodent models have
been developed to elucidate the etiology and pathogenesis of
EOC. However, the artificial nature of the induced tumors in mice
limits their clinical relevance [6,7,8]. Meanwhile, the laying hen is
well known as the only animal that spontaneously develops tumors
from ovarian surface epithelium, and the laying hen is a unique
and suitable model to develop novel biomarkers and anti-cancer
drugs for patients with EOC [6,7,9].
Serpin peptidase inhibitor, clade B, member 3 (SERPINB3) is a member
of the serpin superfamily of protease inhibitors involved in
apoptosis, immune response, blood coagulation, cell migration
and invasiveness of cells [10,11]. It is also known as squamous cell
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carcinoma antigen 1 (SCCA1) first discovered in squamous cell
carcinoma of the cervix [12]. In humans, the gene for SERPINB3
is located on chromosome 18q21.3, and it inhibits papaine-like
lysosomal cysteine proteases, cathepsin K (CTSK), CTSL and
CTSS [10,13]. Previously, we identified SERPINB3 in chickens
and determined that it has moderate homology to its mammalian
protein orthologue (approximately 36–47%). Avian SERPINB3 is
expressed in the oviduct in response to estrogen in a tissue- and
cell-specific manner [14]. Nevertheless, little is known about the
expression and prognostic value of SERPINB3 in either chickens or
humans with EOC.
MicroRNAs (miRNAs) are small and non-coding RNAs of 18–
23 nucleotides in length. Those regulate gene expression post-
transcriptionally and are also able to alter cell fate by controlling
translation of target mRNAs in diverse tissues and cell types.
Therefore, miRNAs play crucial roles in a various biological
processes including vertebrate growth, development, differentia-
tion and oncogenesis by regulating gene expression [15,16,17].
However, there are not published results of miRNA research
related with SERPINB3 in chickens. In order to determine the
role of SERPINB3 as a novel biomarker for EOC, we compared
the distribution and localization of SERPINB3 between normal
and cancerous ovaries of laying hens, and then we performed a
miRNA target validation assay to investigate post-transcriptional
regulation of SERPINB3 expression. After that we compared
SERPINB3 expression among normal and cancer cells of ovaries
from laying hens, human EOC cell lines (OVCAR-3 and SKOV-
3) and a human ovarian teratocarcinoma cell line (PA-1). Finally,
we investigated the diagnostic and prognostic values of SERPINB3
expression in patients with EOC.
Results
Expression and Localization of SERPINB3 mRNA and
Protein in Normal and Cancerous Ovaries of Laying Hens
Comparisons of expression of SERPINB3 mRNA between
normal and cancerous ovaries of laying hens by RT-PCR revealed
that it was expressed in only cancerous ovaries (Fig. 1A and 1B).
Moreover, quantitative RT-PCR showed that SERPINB3 mRNA
was induced only in cancerous ovaries (P,0.01; Fig. 1C). These
results suggest that SERPINB3 is a biomarker for epithelia-derived
ovarian cancer in laying hens.
In situ hybridization analysis demonstrated that SERPINB3
mRNA was abundant in the glandular epithelium of cancerous
ovaries of laying hens (Fig. 2A), but was not detectable in the
stroma, blood vessels or immune cells of cancerous ovaries.
Consistent with these results, SERPINB3 protein was detected
predominantly in the cytoplasm of glandular epithelium in
cancerous, but not normal ovaries of laying hens (Fig. 2B). These
results indicate that SERPINB3 is specifically expressed only in the
glandular epithelium of cancerous ovaries of laying hens.
Post-transcriptional Regulation of microRNAs Affecting
SERPINB3
To investigate the possibility that SERPINB3 expression is
regulated at the post-transcriptional level by miRNAs, we
performed a miRNA target validation assay. Analysis of potential
miRNA binding sites within the 39-UTR for SERPINB3 using a
miRNA target prediction database (miRDB; http://mirdb.org/
miRDB/) revealed three putative binding site for miR-101, miR-
1668 and miR-1681 (Figure 3A). Therefore, we determined if these
three miRNAs influenced SERPINB3 expression via its 39-UTR. A
fragment of the SERPINB3 39-UTR harboring binding sites for the
miRNAs was cloned downstream of the green fluorescent protein
(GFP) reading frame, thereby creating a fluorescent reporter for
function of the 39-UTR region. In addition, SERPINB3 39-UTR
mutants including mutated binding sites for miR-101, miR-1668
and miR-1681 were also generated by point mutation in order to
confirm the modulation of eGFP expression by each miRNA
(Figure 3B). After co-transfection of eGFP-SERPINB3 39-UTR and
DsRed-miRNA, the intensity of GFP expression and percentage of
GFP-expressing cells were analyzed by fluorescence microscopy
and FACS (Figure 3C and 3D). In the presence of miR-101, miR-
1668 and miR-1681, the intensity and percentage of GFP-
expressing cells (44.8% in control vs. 27.5% in miR-101, 24.2%
in miR-1668, 14.8% in miR-1681) decreased (p,0.01). However,
when there was co-transfection of eGFP-SERPINB3 39-UTR
mutants, the intensity and percentage of GFP-expressing cells were
not changed (14.8% in control vs. 16.1% in miR-101, 13.5% in
miR-1668, 14.3% in miR-1681) as a control (Figure 3D). These
results indicate that these three miRNAs directly bind to the
SERPINB3 transcript and post-transcriptionally regulate SER-
PINB3 gene expression.
Immunofluorescence Detection of SERPINB3 Protein in
Chicken and Human Ovarian Cancer Cells
To compare the expression patterns of SERPINB3 protein
between chicken and human ovarian cancer cells, we conducted
immunofluorescence analysis. SERPINB3 protein was rarely
detected in normal cells, but abundant in the nucleus of ovarian
cancer cells of laying hens (Fig. 4A). Similarly, SERPINB3 protein
was abundant in the nucleus of three human ovarian cancer cell
lines, OVCAR-3, SKOV-3 and PA-1 cells (Fig. 4B).
SERPINB3 Protein Expression is Associated With Platinum
Resistance and Survival in Patients with Epithelial Ovarian
Cancer
A total of 109 patients with a median age of 52 years (range, 23–
82 years) were enrolled in the current study. Among all patients,
38 (34.9%) were in FIGO stage I, 20 (18.3%) in stage II, and 51
(46.8%) in stage III. Tumor grade was G1 in 21 (19.3%), G2 in 41
(37.6%) and G3 in 47 patients (43.1%). Histologically, 62 tumors
(57%) were diagnosed with serous carcinoma, 17 (15.6%) with
mucinous carcinoma, 12 (11%) with clear cell carcinoma, 9 (8.3%)
with endometrioid carcinoma, 4 (3.6%) with undifferentiated
carcinoma, and 3 (2.7%) with endometrioid and clear cell
carcinoma, and 2 (1.8%) with serous and clear cell carcinoma.
Optimal cytoreductive surgery was performed in 65 patients
(59.6%), whereas 44 (40.4%) underwent suboptimal cytoreductive
surgery. Ninety patients (82.6%) received adjuvant chemotherapy
after surgery, and 84 (93.3%) received paclitaxel/carboplatin
while paclitaxel/cisplatin was administered to 6 (6.7%) patients.
Results of immunohistochemistry analysis revealed that SER-
PINB3 protein was detected predominantly in glandular epithe-
lium as for the laying hen model, and 15 (13.8%), 66 (60.6%) and
28 (25.7%) patients had weak, moderate and strong expression of
SERPINB3 protein in ovarian glandular epithelium, respectively
(Fig. 5).
The median time to follow-up was 69.2 months (range, 2–88
months), and 70 patients (77.8%) showed platinum sensitivity
while 20 (22.2%) demonstrated platinum resistance. Strong
expression of SERPINB3 protein was more frequent in patients
with platinum resistance (n = 11, 55%) than in those with platinum
sensitivity (n = 17, 24.3%) (P=0.01). Strong expression of
SERPINB3 protein was also an independent prognostic factor
for platinum resistance after adjustments using clinic-pathologic
factors (adjusted OR; odds ratio, 5.94; 95% CI, 1.21–29.15)
SERPINB3 as a Prognostic Factor for Ovarian Cancer
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(Table 1). Strong expression of SERPINB3 was associated with
shorter PFS than weak or moderate expression (mean PFS were
25.7 vs. 47.8 months; P=0.03) in spite of no difference in OS
(mean OS; overall survival, 49.5 vs. 60.9 months; P.0.05).
Furthermore, SERPINB3 was a poor prognostic factor for PFS
(Progression-free survival) using multivariate Cox’s proportional
hazard analysis (adjusted HR; hazard ratio, 2.07; 95% CI;
confidence interval, 1.03–4.41; Table 2), whereas there was no
prognostic factor value for OS except suboptimal cytoreduction
(adjusted HR, 6.83; 95% CI, 2.34–20.02).
Discussion
The laying hen is a well-known model for investigation of
ovarian carcinogenesis and for development of anti-cancer
agents for women because of the similarity in spontaneously
arising carcinomas from epithelial ovarian cells [18]. Histology,
metastasis and stages of EOC in laying hens are similar to those
in humans which indicates the feasibility of using the laying hen
model for investigating ovarian carcinogenesis [6]. Furthermore,
several biomarkers, including CA-125, are commonly expressed
and used for detecting early-stage disease and monitoring
therapeutic response in women with EOC and they are cross-
reactive with biomarkers for EOC in laying hens [18,19].
In general, a number of complex glandular architectures are
usually found in various carcinomas that arise in various organs
such as stomach, bronchus, gladder, prostate, testis and ovary
due to the ubiquitous nature of glands. Especially, in ovaries of
both avian and mammalian species, these glandular structures
are mainly in endometrioid-type tumors with several character-
istics such as nuclear atypia, cribriform foci and atresia of
stromal follicles. In addition, the glands of adenocarcinomas in
women consist of a single layer of epithelial cells undergoing
mitosis and sharp luminal margins [6]. Our preliminary results
also showed that the glandular architecture in primary ovarian
epithelial carcinomas of laying hens is composed of a labyrinth
of glands or lacelike papillary folding with large plieomorphic
nuclei containing mitotic figures as previously reported [6]. The
current study to find a novel prognostic biomarker for patients
with EOC using the laying hen model identified high expression
of SERPINB3 gene in glandular epithelium of cancerous ovaries
compared to that in normal ovaries from hens. The results
suggest that SERPINB3 may be associated with ovarian
carcinogenesis through the activation of transcription factors
or the inhibition of apoptosis. Our results also revealed that
Figure 1. Expression and quantitation of SERPINB3 mRNA in normal and cancerous ovaries of laying hens. RT-PCR analysis was
performed using cDNA templates from chicken SERPINB3 and GAPDH-specific primers. [A] Lanes 1 to 4 show four different normal ovaries and N is
negative control. [B] Lanes 1–10 show 10 different cancerous ovaries. [C] Quantitative RT-PCR analysis was performed using cDNA templates from
normal and cancerous ovaries of laying hens (mean 6 SEM; P,0.01).
doi:10.1371/journal.pone.0049869.g001
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SERPINB3 gene expression is post-transcriptionally regulated by
several miRNAs critical to development of the chicken ovarian
carcinogenesis. Furthermore, strong expression of SERPINB3
protein was related to platinum resistance and shorter progres-
sion-free survival in patients with EOC. These findings support
our hypothesis that SERPINB3 plays a role in tumor
development and proliferation from ovarian epithelial cells.
Although the functional role of SERPINB3 gene in EOC biology
is not known, results of the present study indicate clearly that
SERPINB3 is associated with glandular morphogenesis affecting
Figure 2. Expression of SERPINB3mRNA and protein is unique to glandular epithelium of cancerous ovaries from laying hens. [A] In
situ hybridization analyses of SERPINB3 mRNA. Cross-sections of normal and cancerous ovaries from laying hens were hybridized with sense or anti-
sense chicken SERPINB3 cRNA probes. [B] Immunohistochemical expression of SERPINB3 protein: For negative control, the primary antibody was
substituted with purified non-immune mouse IgG. F, follicle; GE, glandular epithelium; S, stroma; Scale bar represents 200 mm (the first columnar
panels and sense) or 50 mm (the second columnar panels).
doi:10.1371/journal.pone.0049869.g002
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ovarian carcinogenesis in both hens and women with EOC. In
both women and hens, SERPINB3 is expressed in the glandular
epithelium, but there is little or no SERPINB3 expression in other
tissues and cells including stroma and blood vessels of the ovary.
These findings indicate that SERPINB3 protein may activate
transcription factors or inhibit apoptosis leading to development of
EOC in laying hens and women. In previous studies, SERPINB3
was found to regulate programmed cell death by different
mechanisms in various cancers and its over-expression was
characteristic of cancerous cells of epithelial origin. In addition,
SERPINB3 attenuates apoptosis mediated by anti-cancer drugs for
NK cells and by inhibiting cytochrome c release from the
mitochondria [20,21,22] Moreover, glandular morphogenesis
associated with SERPINB3 may contribute to epithelial-mesen-
chymal transition, which may deregulate the adhesion process to
allow metastasis and increase the invasiveness potential of tumor
cells in women [23].
Figure 3. In vitro target assay of microRNAs on the SERPINB3 transcript. [A] Diagram of miR-101, miR-1668 and miR-1681 binding sites in
SERPINB3 39-UTR. [B] Expression vector maps for eGFP with SERPINB3 39-UTR and mutated SERPINB3 39-UTR and Ds-Red with each miRNA. The wild-
type (WT) and mutants of 39-UTR of the SERPINB3 transcript were subcloned between the eGFP gene and the polyA tail to generate the fusion
construct of the GFP transcript following the miRNA target 39-UTR (pcDNA-eGFP-39UTR) (top and middle panel) and the miRNA expression vector was
designed to co-express DsRed and each miRNA (pcDNA-DsRed-miRNA) (bottom panel). [C] After co-transfection of pcDNA-eGFP-39UTR for the
SERPINB3 transcript and pcDNA-DsRed-miRNA for the miR-101, miR-1668 and miR-1681, the fluorescence signals of GFP and DsRed were detected
using fluorescent microscopy. [D] The rate of inhibition of eGFP expression from miRNA modulation was calculated by fluorescence-activated cell
sorting (FACS). Solid bars represent WT of SERPINB3 39-UTR and empty bars show the mutant of SERPINB3 39-UTR for each miRNA. Error bars indicate
the standard error of triplicate analyses. The asterisks denote statistically significant differences between WT vs. mutants (***P,0.001).
doi:10.1371/journal.pone.0049869.g003
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Strong expression of SERPINB3 was also associated with
platinum resistance and shorter PFS in patients with EOC. The
mechanism responsible for development of chemoresistance and a
potential role for SERPINB3 has not been established in EOC.
Nevertheless, dysfunctional permeabilization of lysosomes con-
tributes to the development of chemoresistance in ovarian cancer
cells [24], and SERPINB3 confers resistance to drug-induced
apoptosis by inhibiting lysosomal cathepsin proteases in cancer
cells [25]. Thus, SERPINB3 may contribute to platinum resistance
following chemotherapy-induced lysosomal destabilization. Al-
though strong expression of SERPINB3 was associated with
shorter PFS, it is possible that platinum resistance associated with
SERPINB3 leads to shorter PFS. This fact is supported by a
previous study in which SERPINB3 expression was found to be
associated with poor survival in patients with breast cancer [26].
SERPINB3 or SCCA1 has been investigated in various types of
squamous cell carcinoma [27,28,29,30], but it has only been
suggested as a prognostic factor for breast cancer and lung
adenocarcinoma [26,31]. To our knowledge, results of the current
study are significant in being the first to establish the likelihood of a
functional role for SERPINB3 in EOC of laying hens. These
results validate the laying hen as a model for research on human
EOC. Further, the results strongly suggest that SERPINB3 has
important functions in development of EOC in laying hens and
that it is a novel biomarker for predicting platinum resistance and
poor PFS in patients with EOC. Our hypothesis that SERPINB3
has a specific role in development of human EOC requires further
evaluation in clinically prospective studies.
Materials and Methods
Experimental Animals and Animal Care and Use
The experimental use of chickens in the present study was
approved by the Institute of Laboratory Animal Resources, Seoul
National University. White Leghorn (WL) laying hens were
managed according to approved standards for operation of the
University Animal Farm, Seoul National University, Korea. All
hens had free ad libitum access to feed and water.
Tissue Samples in Chicken Model
A total 136 laying hens (88 over 36 months and 48 over 24
months of age), which had stopped laying eggs, were euthanized
for biopsy and collection of cancerous (n = 10) ovaries. As a
control, normal (n = 5) ovaries were collected from egg-laying hens
of similar age. We examined tumor stages in 10 hens with
cancerous ovaries based on characteristic features of chicken
ovarian cancer [6]. Three hens had Stage III EOC as ovarian
tumor cells had metastasized to the gastrointestinal tract and liver
surface with profuse ascites in the abdominal cavity. In five hens,
their tumors had metastasized to distant organs such as liver
parenchyma, lung, gastrointestinal tract and oviduct with profuse
ascites which is indicative of Stage IV EOC. The other two hens
did not have tumors in any other organs; therefore, their ovarian
tumors were classified as stage I EOC. Subsets of these samples
were fixed in 4% paraformaldehyde for further analyses. After
24 h, fixed tissues were changed to 70% ethanol for 24 h and then
dehydrated and embedded in Paraplast-Plus (Leica Microsystems,
Wetzlar, Germany). Hens with EOC were classified based on their
cellular subtypes and patterns of cellular differentiation with
reference to human ovarian malignant tumor types [6].
RNA Isolation
Total cellular RNA was isolated from frozen tissues using Trizol
reagent (Invitrogen, Carlsbad, CA) according to the manufactur-
er’s recommendations. The quantity and quality of total RNA was
determined by spectrometry and denaturing agarose gel electro-
phoresis, respectively.
Semi-quantitative RT-PCR Analysis
The expression of SERPINB3 mRNA in normal and cancerous
ovaries of hens was assessed using semi-quantitative RT-PCR as
described previously [32]. Complementary DNA (cDNA) was
synthesized from total cellular RNA (2 ug) using random hexamer
(Invitrogen, Carlsbad, CA) and oligo (dT) primers and AccuPo-
werH RT PreMix (Bioneer, Daejeon, Korea). The cDNA was
diluted (1:10) in sterile water before use in PCR. After PCR, equal
amounts of reaction product were analyzed using a 1% agarose
Figure 4. Immunofluorescence microscopy detected SERPINB3 protein in ovarian cancer cell lines of both women and laying hens.
[A] SERPINB3 protein was rarely detected in normal cells, but abundant in the nuclei of chicken ovarian cancer cells. [B] SERPINB3 protein was
expressed in nuclei of human OVCAR-3, SKOV-3 and PA-1 cells. Cell nuclei were stained with DAPI (blue). All images were captured at 40X objective
magnification.
doi:10.1371/journal.pone.0049869.g004
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gel, and PCR products were visualized using ethidium bromide
staining.
Quantitative RT-PCR Analysis
Gene expression levels were measured using SYBRH Green
(Sigma, St. Louis, MO, USA) and a StepOnePlusTM Real-Time
PCR System (Applied Biosystems, Foster City, CA, USA).[33]
The GAPDH gene was simultaneously analyzed as a control and
used for normalization to account for variation in loading. Each
target gene and GAPDH was analyzed in triplicate. ROX dye
(Invitrogen) was used as a negative control for the fluorescence
measurements. Sequence-specific products were identified by
generating a melting curve in which the CT value represented
the cycle number at which a fluorescent signal was statistically
greater than background, and relative gene expression was
quantified using the 2–DDCT method [34]. For the control, the
relative quantification of gene expression was normalized to the
CT of the control ovary.
In Situ Hybridization Analysis
For hybridization probes, PCR products were generated and
were gel-extracted and then cloned into pGEM-T vector
(Promega) as described previously [35]. After verification of the
sequences, plasmids containing the correct gene sequences were
amplified with T7- and SP6-specific primers then digoxigenin
(DIG)-labeled RNA probes were transcribed using a DIG RNA
labeling kit (Roche Applied Science, Indianapolis, IN). After
hybridization and blocking, the sections were incubated overnight
with sheep anti-DIG antibody conjugated to alkaline phosphatase
(Roche). The signal was visualized by exposure to a solution
containing 0.4 mM 5-bromo-4-chloro-3-indolyl phosphate,
0.4 mM nitroblue tetrazolium, and 2 mM levamisole (Sigma).
MicroRNA Target Validation Assay
The 39-UTR of SERPINB3 was cloned and confirmed by
sequencing. The 39-UTR was subcloned between the eGFP gene
and the bovine growth hormone (bGH) poly-A tail in
pcDNA3eGFP (Clontech, Mountain View, CA) to generate the
eGFP-miRNA target 39-UTR (pcDNA-eGFP-39-UTR) fusion
constructs. In addition, mutants of SERPINB3 39-UTR for each
miRNA were generated by point mutation and then cloned into
the same type of plasmids. For the dual fluorescence reporter
assay, the fusion constructs containing the DsRed gene and either
miR-101, miR-1668 and miR-1681 were designed to be co-
expressed under control of the CMV promoter (pcDNA-DsRed-
miRNA). The pcDNA-eGFP-39-UTR and pcDNA-DsRed-
miRNA (4mg) were co-transfected into 293FT cells using the
calcium phosphate method. When the DsRed-miRNA is ex-
pressed and binds to the target site of the 39-UTR downstream of
the GFP transcript, green fluorescence intensity decreases due to
degradation of the GFP transcript. At 48 h post-transfection, dual
fluorescence was detected by fluorescence microscopy and
calculated by FACSCalibur flow cytometry (BD Biosciences).
For flow cytometry, the cells were fixed in 4% paraformaldehyde
and analyzed using FlowJo software (Tree Star Inc., Ashland,
OR).
Cell culture
A total of five cell lines, including three human ovarian
epithelial cancer and two chicken primary ovarian cells, were used
in this study. Human ovarian cancer cell lines (OVCAR-3,
SKOV-3, and PA-1) were obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA) and cultured
according to supplier’s directions. Two different chicken ovarian
surface epithelial cells (normal and cancerous cells) were isolated
and cultured as previously described with some modifications
[36,37].
Immunofluorescence Microscopy for Detection of
SERPINB3 Activation
Ovarian cancer cells and normal ovarian cells obtained from
laying hens, and three human ovarian cancer cell lines, OVCAR-
3, SKOV-3, and PA-1, were examined for SERPINB3 expression
patterns by immunofluorescence microscopy as described previ-
ously. Each type of cell was seeded onto Lab-Tek chamber slides
(Nalge Nunc International, Rochester, NY). After 24 h, cells were
fixed with220uC methanol and immunofluorescence staining was
performed using an anti-human SERPINB3 monoclonal antibody
(catalog number: ab55733; Abcam plc, Cambridge, UK). Cells
were then incubated with Alexa Fluor 488 Rabbit anti-goat IgG
Figure 5. Immunohistochemistry was used to demonstrate expression of SERPINB3 protein in cancerous ovaries, but not in normal
ovaries from women. (a and a9) Weak, (b and b9) moderate and (c and c9) strong expression of SERPINB3 protein was detected in women with
epithelial ovarian cancer. There was either no expression of very weak expression of SERPINB3 in normal ovaries, whereas SERPINB3 protine was easily
detectable in cancerous ovaries from women. The negative control used was mouse IgG instead of primary antibody. Scale bar represents 200 mm
(the first horizontal panels and IgG) or 50 mm (the second horizontal panels).
doi:10.1371/journal.pone.0049869.g005
Table 1. Multivariate linear logistic regression analysis for
factors affecting platinum resistance.
Characteristics Adjusted OR2 95% CI3 p value
Age $52 years 0.93 0.25–3.41 0.91
FIGO stage III disease1 3.06 0.48–19.56 0.24
Grade 3 disease 4.36 1.14–16.71 0.03
Serous adenocarcinoma 0.49 0.11–2.12 0.34
Suboptimal cytoreduction 36.63 5.35–25.07 ,0.01
Strong expression of SERPINB3 5.94 1.21–29.15 0.03
Abbreviation: FIGO, International Federation of Gynecology and Obstetrics; OR,
odd ratio; CI, confidence interval.
doi:10.1371/journal.pone.0049869.t001
Table 2. Multivariate Cox’s proportional hazard analysis for
poor prognostic factors affecting progression-free survival.
Characteristics Adjusted HR2 95% CI3 p value
Age $52 years 1.16 0.62–2.17 0.63
FIGO stage III disease1 1.49 1.63–3.50 0.01
Serous adenocarcinoma 1.18 0.58–2.40 0.73
Grade 3 disease 1.34 0.76–2.52 0.85
Suboptimal cytoreduction 5.37 2.39–12.07 ,0.01
Strong expression of SERPINB3 2.07 1.03–4.41 0.04
Abbreviation: FIGO, International Federation of Gynecology and Obstetrics; HR,
hazard ratio; CI, confidence interval.
doi:10.1371/journal.pone.0049869.t002
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secondary antibody (A21222, Invitrogen). Slides were overlayed
with DAPI before images were captured using a Zeiss confocal
microscope LSM710 (Carl Zeiss) fitted with a digital microscope
camera AxioCam and Zen 2009 software.
Human Study Population
Clinical data were retrieved from a database of patients with
EOC between June 2003 and March 2009. Approval by the
Institutional Review Board of Seoul National University Bundang
Hospital was obtained in advance for the current study. The
eligibility criteria were as follows for the patients: they were
diagnosed with EOC; they were treated with maximal cytoreduc-
tive surgery followed by adjuvant taxane- and platinum-based
chemotherapy if indicated; they had Eastern Cooperative Oncol-
ogy Group performance status of 0–2; and they had no underlying
disease affecting survival. _ENREF_4Optimal cytoreductive sur-
gery was defined as a residual tumor #1 cm, whereas suboptimal
cytoreductive surgery was defined as a residual tumor .1 cm in
maximal diameter. All patients except those with low-risk early-
stage disease such as FIGO stage IA or IB with grade 1 or 2
disease received adjuvant chemotherapy using paclitaxel (175 mg/
m2)/carboplatin (AUC 5.0) or paclitaxel (175 mg/m2)/cisplatin
(75 mg/m2) for 1–2 weeks after surgery, and the chemotherapy
was repeated every 3 weeks for 6 cycles. Progression-free survival
(PFS) was defined as the time elapsed from the date of completion
of primary adjuvant chemotherapy to the date of clinically proven
aggravation. Overall survival (OS) was calculated from the date of
staging laparotomy to the date of cancer-related death or the end
of the study. Platinum resistance was defined as the response to
platinum-based chemotherapy with a minimum treatment-free
interval of less than 6 months while platinum sensitivity was
defined as the response to platinum-based chemotherapy with a
minimum treatment-free interval of greater than or equal to 6
months.
Immunohistochemistry
The localization of SERPINB3 protein in normal and
cancerous ovaries of hens was evaluated by immunohistochemistry
(IHC) _ENREF_21using an anti-human SERPINB3 monoclonal
antibody at a final dilution of 1:500 (1 mg/ml), and antigen
retrieval was performed using the boiling citrate method as
described previously [33]. Negative controls included the substi-
tution of the primary antibody with purified non-immune mouse
IgG at the same final concentration. For IHC of human ovarian
cancer tissues, representative core tissue sections (2 mm in
diameter) were taken from paraffin blocks and arranged in new
tissue microarray (TMA) blocks using trephine apparatus (Superb-
iochips Laboratories, Seoul, Korea). In cases with variable
histologic features, the most representative area was selected for
TMA construction. The IHC staining of human TMA samples
was performed using similar methods for the laying hen model.
After IHC, the results were assessed semi-quantitatively by one
pathologist unaware of clinico-pathologic characteristics. All EOC
tissues showed nuclear staining in most tumor cells, whereas no
nuclear staining was observed in normal human ovarian tissues
and the negative control where the primary antibody was
substituted with purified non-immune mouse IgG at the same
concentration. Thus, the staining intensity of tumor cells was
graded as weak (1+), moderate (2+) or strong (3+).
Statistical Analysis
In order to investigate the role of SERPINB3 as a novel
biomarker of ovarian carcinogenesis in the laying hen model and
to predict clinical outcomes in patients with EOC, data were
subjected to analysis of variance, Chi-squared and Student’s t-tests,
Kaplan-Meier method with the log-rank test, logistic regression
and Cox’s proportional hazard analyses to determine odds ratio
(OR), hazard ratio (HR), and 95% confidence interval (CI).
Statistical analyses were performed using Excel (Microsoft, Red-
mond, WA, USA) and SPSS software (Version 19.0; SPSS Inc.,
Chicago, IL, USA). A probability value of P,0.05 was considered
statistically significant.
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